Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Research
  • Owkin, Servier ink oncology R&D deal to guide discovery and trial design

Owkin, Servier ink oncology R&D deal to guide discovery and trial design

September 11, 2026Posted inResearch

AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.

Post navigation

Previous Post
mt2m:-cost-driven-strategy-for-cyber-defense-under-changing-constraints MT2M: Cost-Driven Strategy for Cyber Defense Under Changing Constraints
Next Post
Dynamic graph-based reinforcement learning enables autonomous quadrotor navigation dynamic-graph-based-reinforcement-learning-enables-autonomous-quadrotor-navigation

Recent Posts

  • Diatom Biofilm Feeds Rare Cave Brittle Stars
  • Machine Learning Decodes Osmanthus White Tea Scenting
  • Hymenoptera Chromosome Research Shifts to Cytogenomics
  • Ancient Sanctuary Reveals Hidden Reptile Diversity on Greek Island
  • AI Reads CT Scans to Predict Bladder Cancer Recurrence Before It Happens

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top